CompletedNCT00814957
An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand
Medication studyAges 30–55United KingdomAddiction
Understand this study
Who was this study for?
Listed age limits: 30 years to 55 years.
- Listed locations
- HarrowSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: December 8, 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 12
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 30 Years to 55 Years
- Official registry ID
- NCT00814957
- Official title
Show the full official title
An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain Dopamine D3 Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK618334, Using 11C-PHNO as PET Ligand.
Get this study by email
Recruitment & locations
CompletedHarrow
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including GSK618334.
Who was this study for?
Listed age limits: 30 years to 55 years.
Want to explore more studies?
Explore studiesRelated studies
A phase II, randomised, double-blind, placebo- controlled, multi-site, parallel group clinical trial to examine ketamine as a pharmacological treatment for alcohol dependence in an alcohol dependen...
A Study of Oral Ibogaine in Opioid Withdrawal